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Prepared for the Investigator Group by CHRISTIAN R. KLIMT, GENELL L. KNATTERUD, 
JEREMIAH STAMLER, FACe, PAUL MEIER* 
In the Persantine-Aspirin Reinfarction Study, Part II 
(PARIS II), 3,128 persons who had recovered from myo•
cardial infarction, suffered from 4 weeks to 4 months 
previously, were randomized into two groups: dipyrid•
amole (Persantine) plus aspirin (n = 1,563) and placebo 
(n = 1,565). The average length of follow-up was 23.4 
months. Prespecified primary end points were coronary 
incidence (definite nonfatal myocardial infarction plus 
death due to recent or acute cardiac event), coronary 
mortality (death due to recent or acute cardiac event) 
and total mortality, each at 1 year of patient follow-up 
and at the end of the study. 
Coronary incidence in the Persantine plus aspirin 
group was significantly lower than in the placebo group, 
both at 1 year (30% reduction) and at the end of the 
study (24% reduction). The statistically significant dif•
ferences in coronary incidence, at 1 year and at the end 
of the study, in favor of the combination treatment re•
mained after adjustment for multiple baseline variables 
and adjustment for multiple testing (three end points for 
two time periods). Although there were reductions for 
The Persantine-Aspirin Reinfarction Study, Part II (PARIS 
II) was a randomized, controlled, double-blind trial de•
signed to test the efficacy of the combination of Persantine 
(dipyridamole) and aspirin in the long-term therapy of coro•
nary heart disease in men and women recently recovered 
from myocardial infarction. It has long been established that 
blood platelets, or more specifically platelet aggregation, 
playa fundamental role in initiating thrombus formation in 
arteries (1,2). Acute myocardial infarction and sudden death 
may be a result of platelet aggregates forming in arteries or 
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other end points, these differences were not statistically 
significant. Coronary mortality was 20% lower in the 
Persantine plus aspirin group compared with the placebo 
group at 1 year, and 6% lower overall. Total mortality 
in the treated group compared with the placebo group 
was 11 % lower at 1 year and 3% lower overall. The 
reduced rates of coronary incidence largely reflected lower 
rates of definite nonfatal ntyocardial infarction in the 
Persantine plus aspirin group. 
Several subgroups were defined a priori and at the 
end of the study. The beneficial effect of Persantine plus 
aspirin compared with placebo for coronary incidence 
tended to be greater for the following groups of patients: 
those who had a non-Q wave infarct; those who were 
not taking digitalis; those who were receiving beta-re•
ceptor blocking drugs at baseline; those who were in 
New York Heart Association functional class I; those 
who had had only one myocardial infarction; or those 
who were enrolled in the study early, that is within 85 
days of the qualifying myocardial infarction. 
(J Am Coli CardioI1986;7:251-69) 
in the microcirculation of the heart. It is reasonable to expect 
that if the incidence of thrombosis and embolization is re•
duced, then. perhaps as a consequence, mortality and mor•
bidity from myocardial infarction will be reduced. The latter 
possibility is the rationale for testing the hypothesis that 
long-term inhibition of platelet aggregation in high risk in•
dividuals may have a beneficial effect. 
Dipyridamole and aspirin both influence platelet function 
in ways that impede thrombogenesis (3-12) and are prom•
ising antithrombotic agents for prophyiactic use in pre•
venting arterial thrombosis in humans. Additionally, di•
pyridamole and aspirin appear to potentiate each other's 
inhibitory effects on thrombosis in small vessels 03-15). 
A dose-dependent increase in the potentiation of dipyrida•
mole by aspirin has been reported with dosages approxi•
mately the same as those used in this study (\6). The com•
bination has been shown to be successful in reducing the 
rate of occlusion of coronary artery bypass grafts (17,18). 
The first Persantine-Aspirin Reinfarction Study (PARIS) 
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(to avoid confusion, the original PARIS wilI heareafter be 
referred to as PARIS I), completed in 1979, evaluated a 
combination of Persantine (dipyridamole) and aspirin (19). 
Patients were randomized 8 weeks to 5 years after an acute 
myocardial infarction to treatment with Persantine plus as•
pirin, aspirin alone or placebo. At the end of PARIS I, rates 
of death, coronary death (death due to recent or acute cardiac 
event) and coronary incidence (defined as definite nonfatal 
myocardial infarction or coronary death) were lower for both 
active treatment groups compared with the placebo group, 
but the differences were not statisticaIIy significant at the 
end of the study. Differences in rates of coronary incidence 
between placebo and the Persantine-aspirin combination 
treatment for the first 24 months of treatment were statis•
tically significant. The combination treatment showed a small 
nonsignificant advantage over aspirin alone for coronary 
mortality and coronary incidence for the first 20 months of 
treatment. Post hoc analyses showed that the subgroup of 
patients enrolled within 6 months of their qualifying myo•
cardial infarction who were randomized to active treatment, 
particularly the Persantine-aspirin group. had the largest 
absolute and proportionate reductions in total and coronary 
mortality. 
At the conclusion of PARIS I, the study Policy Board 
recommended to the sponsor that another study of Persantine 
and aspirin be conducted with patients enrolIed closer in 
time to their qualifying myocardial infarction. The design 
of the study was finalized based on detailed review of the 
issues of number of patients required, recruitment potential, 
statistical power, cost and the state of knowledge concerning 
the efficacy of antiplatelet drugs after completion of the 
Aspirin Myocardial Infarction Study (AMIS) (20) and PARIS 
I (19). These considerations led to a two-group design, 
rather than the three-group design of PARIS I, with 3.000 
patients to be randomized to dipyridamole plus aspirin or 
to placebo. The primary aim was to test the efficacy of 
dipyridamole plus aspirin compared with placebo in persons 
aged 30 to 74 years recruited within 4 weeks to 4 months 
of a verified myocardial infarction. Three end points. each 
to be examined after I year of patient folIow-up and for the 
total follow-up period. were selected as the determinants of 
efficacy. These end points were total mortality. coronary 
mortality, and coronary incidence as defined for PARIS I. 
Thus, there were six primary end points, three defined events 
for each of two specified time periods. 
In addition. three a priori subgroup hypotheses were 
formulated based on findings of PARIS I which indicated 
a greater benefit in patients at lower risk of subsequent 
reinfarction. namely: 1) active medication would be more 
beneficial in patients who had had only one myocardial 
infarction (the one that made the patient eligible for PARIS 
II) compared with those with a history of one or more 
myocardial infarctions before the one that made the patient 
eligible for PARIS II; 2) efficacy would be greater in patients 
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classified in New York Heart Association functional class 
I (no limitation of ordinary physical activity) versus class 
II (slight limitation) (21); and 3) efficacy would be greater 
in patients not taking digitalis at entry compared with those 
taking this drug. During the course of recruitment for the 
trial it became evident that a sizable proportion of eligible 
patients were receiving treatment with a beta-receptor block•
ing agent, and a further hypothesis was formulated based 
on interim findings (October 1982 data), namely: 4) dipyr•
idamole and aspirin would be more efficacious in patients 
prescribed beta-receptor blocking agents compared with those 
not using such medication at baseline. 
Methods 
Study organization. Nineteen of the original 20 PARIS 
I clinics agreed to participate in PARIS II. The Policy Board 
selected an additional 12 clinics to bring the total number 
to 31 (25 in the United States and 6 in Great Britain). The 
PARIS I Coordinating Center at the Maryland Medical Re•
search Institute in Baltimore, Maryland, the Central Lab•
oratory at Bio-Science Laboratories in Van Nuys, Califor•
nia, the ECG Reading Center at the Laboratory of 
Physiological Hygiene at the University of Minnesota and 
the Data Audit Center (formerly the Data Quality Control 
Center) at the University of Chicago also participated in the 
second study (22). Participating institutions and staff and 
committee members are listed in the appendix. 
Patient eligibility criteria. Men and women were eli•
gible for enrolIment if they satisfied the folIowing conditions: 
1) Age 30 to 74 years at the initial visit. 
2) A clinical history, including serum enzyme eleva•
tions. compatible with a diagnosis of myocardial infarction 
and significant electrocardiographic changes determined lo•
cally and verified by the study ECG Center (22). 
3) Time since last documented myocardial infarction of 
4 weeks to 4 months. 
4) Cardiac disease evaluated at the initial visit was class 
I or class II in the 1964 functional classification system of 
the New York Heart Association. Class I includes patients 
with cardiac disease but without resulting limitation of phys•
ical activity; ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnea or anginal pain. Class II in•
cludes patients with cardiac disease resulting in slight lim•
itation of physical activity. They are comfortable at rest. 
Less than ordinary physical activity results in fatigue. pal•
pitation. dyspnea or anginal pain (21). 
5) No previous cardiac or coronary surgery, prosthetic 
valve insertion or permanent pacemaker implantation. (No 
other cardiovascular surgery made an individual ineligible.) 
6) Freedom from life-limiting diseases. that is malig•
nancy, severe pulmonary insufficiency or chronic hepatic 
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disease. Patients with maturity-onset diabetes were eligible 
even if they were insulin dependent. 
7) Free from conditions that would affect long-term fol•
low-up, such as cerebral vascular disease. psychosis. al•
coholism or orthopedic disability. 
8) Free from conditions requiring continuing regular use 
of platelet -affecting drugs. 
9) Free from aspirin hypersensitivity. 
10) Free from upper gastrointestinal bleeding or history 
of clinically significant episodes of bleeding. 
11) Willing to forego use of aspirin or other platelet•
affecting drugs during the study. The patient's physician 
must also have agreed that it was feasible for the patient to 
avoid nonstudy aspirin-containing compounds and other 
platelet-affecting drugs. Acetaminophen was provided by 
the study for patients to use in lieu of aspirin for pain relief. 
12) Not on anticoagulant therapy. 
13) Free from postural hypotension. 
14) Systolic blood pressure less than 200 mm Hg and 
diastolic blood pressure less than 115 mm Hg at the baseline 
visit. 
15) Women not of childbearing potential. 
16) Willing to make scheduled follow-up visits for at 
least 1 year after orientation session. 
17) Willing to give written informed consent. 
Patients were accepted regardless of the number of pre•
vious myocardial infarctions or presence of complications 
during the acute event, provided all other eligibility criteria 
were satisfied. If the patient had been recently hospitalized 
for symptoms suggestive of a myocardial infarction, he or 
she must have been discharged before the initial visit was 
completed. In most clinics, the candidates screened for el•
igibility were patients of the study investigators. The sources 
for recruitment varied by clinic, but were the same as those 
utilized for PARIS I (22). 
Treatment allocation and dosage regimens. Each pa•
tient, after the Coordinating Center staff verified his or her 
eligibility, was randomly allocated to one of two treatment 
groups: Persantine plus aspirin or placebo. The number of 
patients allocated to these two groups was 1.563 and 1,565. 
respectively. The patients in the combination treatment group 
were asked to take one Asasantine capsule three times a 
day. Each Asasantine capsule contained 75 mg of dipyr•
idamole and 330 mg of aspirin. Each patient m the placebo 
group also was asked to take one capsule three times a day. 
The placebo capsules were identical in appearance to Asa•
santine capsules, but contained lactose. The study was dou•
ble-blind with neither the Clinical Center staff nor the patient 
knowing the content of the assigned capsules. 
The randomization schedules used to assign eligible pa•
tients to treatment were prepared by the Coordmating Center 
staff before the trial started and were different for each 
clinic. The schedules provided for balance in the number 
of patients to be assigned to each of the two treatment groups 
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in each clinic using blocks of size eight. No other stratifi•
cation variables were used. 
Examination schedule. Two initial visits were scheduled 
to collect extensive baseline data including a 12 lead rest 
electrocardiogram (22). Randomization occurred at the sec•
ond of these visits, when the patient's eligibility was con•
firmed and the treatment allocation was obtained (by open•
ing the treatment allocation envelope sent from the 
Coordmating Center or by calling the Coordinating Center). 
Fallow-up appointments were scheduled at 1 month and 
then at 4 month intervals after entry. Each visit included 
medical history. physical examination, assessment of ad•
herence to study prescription, local laboratory determina•
tions (hematocrit. white blood cell count, hematuria, urine 
glucose. urine protein) and collection of urine specimens 
for determination of salicylate and dipyridamole levels at 
the Central Laboratory. In addition, at annual visits, fasting 
blood samples were taken and serum specimens forwarded 
to the Central Laboratory for biochemical analyses (urea 
nitrogen. uric acid. creatinine, cholesterol, glucose, potas•
sium. serum glutamic oxaloaceticacid transaminase (SGOT) 
and total bilirubin). A 12 lead rest electrocardiogram was 
taken at the patient's last follow-up visit. Data were recorded 
on standardized forms and sent to the Coordinating Center. 
Copies of key forms also were sent from the Clinical Centers 
directly to the Data Audit Center (22). 
Adherence to study prescription was assessed at each 
follow-up visit by a pill count, questioning of the patient 
by the physician. and collection of urine specimens to be 
analyzed at the Central Laboratory for dipyridamole and 
salicylate metabolites. The results of these latter tests were 
forwarded only to the Coordinating Center and not to the 
clinic. These tests were also conducted on baseline speci•
mens to verify that patients were not using aspirin or di•
pyridamole at the time of enrollment. 
The urine salicylate test is useful to detect the recent 
ingestion of aspirin, but this test will probably not detect 
aspirin taken more than 8 to 12 hours before the time of the 
urine specimen. Positive tests also occur with other salic•
ylate-containing drugs. In this study, aspirin and dipyrid•
amole were given in a single capsule so a positive test for 
dipyridamole would be sufficient evidence that a patient was 
taking the assigned active medication. A positive salicylate 
test could indicate adherence to the active medication but 
might also indicate that the patient was taking known aspirin. 
The primary end points were total mortality, coronary 
mortality and coronary incidence at 1 year of patient follow•
up and for the total study follow-up period. Coronary mor•
tality was defined as death due to an acute or recent cardiac 
event. that is, a cardiac event that resulted in death within 
24 hours of the onset of symptoms or later if the death 
occurred during an uninterrupted hospital stay for a cardiac 
event. Coronary incidence was defined as definite nonfatal 
myocardial infarction or coronary death. Other nonfatal car-
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diovascular events such as suspect recurrent myocardial in•
farction, acute coronary insufficiency, angina pectoris, 
congestive heart failure, stroke, pulmonary embolism and 
cardiovascular surgery were also monitored. Definitions of 
fatal and nonfatal events were given in a previous report 
(22). Reports of mortality, myocardial infarction, acute 
coronary insufficiency, angina pectoris with hospitalization 
and stroke were reviewed by the study Mortality and Mor•
bidity Committee without knowledge of treatment assign•
ment. This committee classified each event according to 
previously defined criteria (22). In cases of disagreement 
between the study physician and this committee, the com•
mittee's classification was taken as final. At least semian•
nually, data reports were prepared at the Coordinating Cen•
ter and independently at the Data Audit Center for review 
by the Data Monitoring Committee. The reports included 
data on the incidence of end points, possible side effects 
and drug reactions, biochemical analyses. quality control 
and patient adherence to protocol prescription. Any disa•
greements between the Coordinating Center and Data Audit 
Center reports were also reviewed at these meetings. 
Study timetable. The original study plan was to enroll 
patients over a I year period beginning in October 1980 and 
to follow all patients to a common termination date in Oc•
tober 1983. Recruitment was slower than expected, perhaps 
partly because of the increase during the 1980s in early 
treatment after myocardial infarction with coronary artery 
bypass graft surgery and because patients with a history of 
bypass surgery were not eligible for the study. To enroll 
3,000 patients, the recruitment period was extended to July 
1983. The follow-up phase of the study was extended to 
July 1984 so that every patient would have at least I full 
year of follow-up. At the time of the decision to extend the 
recruitment and follow-up periods (December 1982), the 
Policy Board also decided to terminate each patient's follow•
up at a closeout visit coinciding with the scheduled second 
annual follow-up visit. Those relatively few patients who 
had already completed 2 years of follow-up had a closeout 
visit at their next scheduled follow-up visit. Beginning in 
March 1984 and continuing through July 1984, all patients, 
including those who had not completed 2 years of follow•
up, were scheduled for a closeout visit with the proviso that 
no patient would have a closeout visit until he or she had 
completed a full year of follow-up. Study treatment was 
discontinued at the closeout visit but neither the patients nor 
the Clinical Center staff were unblinded as to individual 
treatment assignments until August 1984. Deaths and other 
end points were not counted if the event occurred after a 
patient's closeout visit or, in the absence of a closeout visit, 
if the event occurred after July 31, 1984, the final cutoff 
date for the study. Analyses presented here are based on 
the data file as of October 31, 1984. All patients were always 
counted in the treatment groups to which they were origi-
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nally randomized, regardless of considerations such as ad•
herence to study medications or completeness of follow-up. 
Protocol violations. There were five known protocol 
violations in connection with treatment allocation. In one 
case, an allocation was given by telephone to a third party 
in the Clinical Center, but the patient had not in fact com•
pleted the baseline examination. The patient was not entered 
into the study and was immediately lost to follow-up. In 
four other cases, a Change of Status form was submitted to 
the Coordinating Center from a Clinical Center prior to 
completion of the bas'rdine examination, indicating that the 
patient was no longer e~.~gible for the study. However, the 
treatment allocation env~opes were returned opened to the 
Coordinating Center. Th)se patients were also not entered 
into the study. In all five cases, only coded bottle numbers, 
and not actual treatment assignments, were disclosed. The 
life-death status of the latter four persons has been obtained 
and all were alive as of July 31, 1984. 
Data Audit Center review of nonfatal myocardial in•
farction. At the close of the study, the Data Audit Center 
conducted a special review of the classification of nonfatal 
events by the Mortality and Morbidity Committee. This 
review had two objectives: I) clarification of the specific 
criteria used by the committee to diagnose definite myo•
cardial infarction, and 2) verification that all events clas•
sified by the committee as definite myocardial infarction 
met these criteria and that all events not classified as definite 
myocardial infarction did not meet these criteria. The find•
ings of this review are presented at the end of the Results 
section. 
Power and other statistical considerations. Power cal•
culations were made at the beginning of the study assuming 
a 25% reduction in rates for the Persantine and aspirin group 
compared with the placebo group for the primary end points. 
Approximate 2 year PARIS I placebo rates were projected 
for the PARIS II placebo group; these were 8.0, 7.0 and 
14.0% for death, coronary death and coronary incidence, 
respectively. Equal sample sizes of 1,500 were assumed for 
a two-sided Z test of two proportions at the 0.05 level, that 
is, using a critical value of 1.96. Power of this test for total 
mortality, coronary mortality and coronary incidence was 
calculated as 0.54, 0.48 and 0.81, respectively. However, 
it was clear that a critical Z value of 1.96 would be inap•
propriate because six primary end points were specified and 
there would be periodic data monitoring and statistical test•
ing during the course of the study. To take account of this 
analysis plan, a computer simulation procedure was devel•
oped to select an appropriate Z value to apply to the six 
primary analyses at the end of the study. A critical Z value 
of 2.49 was derived (23). Power has not been determined 
exactly for this model but might be expected to be not much 
reduced from that using a single Z test with a critical value 
of 1.96 because even though the critical value used here 
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was much larger, there were more tests and hence more 
opportunities to surpass the critical value. 
Life table rates were calculated using the product-limit 
method (24). Since all patients completed at least 1 full year 
of follow-up, the I year life table rates are the same as the 
crude rates derived by dividing the number of events in the 
first year of follow-up by the total number of patients in the 
group. 
The following formulas were used to compute 95% con•
fidence limits (Ll' L2) on the percent difference between 
proportions (Ph P2) of events in the two treatment groups, 
with nl and n2 patients in the two groups: 
Ll = 100 [(eM!) -1] and L2 = 100 [(eM,) - I), 
where 
and 
s = 
These formulas give results similar to those derived using 
Fieller's theorem (25), but are easier to calculate. 
For the primary end points. life table curves for the two 
treatment groups were compared using the Cox regression 
method (26) to compute the regression coefficient for treat•
ment effect. This method was also used to adjust treatment 
effects for differences in the distributions of various baseline 
variables between the two treatment groups. Baseline vari•
ables were selected for inclusion in the Cox model as ad•
justing variables (covariates) following the principles dis•
cussed by Canner (27). Adjustment for a covariate can be 
expected to alter the estimated treatment effect only if that 
covariate is influential (a change in that covariate corre•
sponds to a change in probability of that event) and also 
disparate (the covariate is not distributed the same in both 
treatment groups). Canner (27) showed that, under reason•
able assumptions, the magnitude of the effect of adjustment 
for a given covariate is proportional to the product of the 
Z value for influence and the Z value for disparity. In the 
present study, every covariate showing significant disparity 
(absolute Z value > 1.96) was included in the set used for 
adjustment. In addition, for each primary end point, influ•
ential covariates were selected using a step-up regression 
procedure (28). The variables considered in the regression 
procedure were those 25 which yielded the highest products 
of the two Z values. From this latter set, the ones selected 
were those which showed significant influence on the end 
point in the regression analysis. 
The treatments were also compared in subgroups of pa•
tients defined by baseline characteristics. Specifically, cer•
tain baseline variables were used to divide patients into two 
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subgroups, for example, digitalis users and nonusers. Then 
the Persantine plus aspirin versus placebo difference in in•
cidence of the end point in the first subgroup was compared 
with that difference in the second (complementary) subgroup. 
A Cox regression model (26) was used to evaluate whether 
treatment effects were different in the two subgroups or 
whether the treatment could be considered as having a com•
mon effect in both subgroups. 
Three prior subgroup hypotheses were specified at the 
beginning of the trial. Based on six primary tests of sig•
nificance (three end points examined at two time points) 
and three subgroup hypotheses, the critical Z value was 
determined to be 2.86 for each test of these subgroup com•
parisons. Tests of significance for the three end points ex•
amined at two time points for all other subgroup hypotheses 
not specified a priori were determined to have a critical Z 
value of 3.53. These critical values (2.86 and 3.53) are 
appropriate for tests to determine whether the Persantine•
aspirin treatment effect in one subgroup is different from 
the treatment effect in the complementary subgroup (such 
as given in column 4 of Table 9); they are not appropriate 
for testing the treatment effect within a given subgroup (such 
as given in column 3 of Table 9). 
Results 
Baseline comparability of treatment groups. Of 179 
baseline characteristics examined, only 13 (7.3%) showed 
a difference in distribution between the two treatment groups 
with a probability value of less than 0.05, which is consistent 
with statistical expectation (Table 1, Part I). Thus, there is 
no reason to question the efficacy of the randomization. The 
mean time from qualifying myocardial infarction to entry 
into the study was 83 days (83.5 for the combination treat•
ment group and 82.4 for the placebo group). The 13 vari•
ables which showed some imbalance between treatment groups 
were listed in Part I of Table 1 and were used as covariates 
in the regression analysis for all end points. 
Additional variables were selected for each end point as 
outlined in Methods. Table 1, Part II compares the distri•
bution between the two treatment groups of other variables 
selected as covariates for one or more of the Cox regression 
analyses. Variables used for adjustment in the analyses of 
total mortality are indicated by letter A in the right-hand 
column of Table 1; the variables used for adjustment of 
analyses of coronary mortality and coronary incidence, by 
letters Band C, respectively. 
For comparison of the two studies, variables selected for 
adjustment in PARIS I (19) that were not included as co•
variates for PARIS II analyses are given in Table 1, Part 
III. The distribution of other baseline characteristics that 
may be considered to be clinically important are given in 
Table 1, Part IV. 
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Table 1. List of Baseline Charactenstics Selected as Adjusting Variables 
Z Value 
BaselIne Variable PR/A PLBO PR/A-PLBO 
I. Van abIes with Z value 2: I. 96 
I Categorical vanables (% of palIents) 
Mantal status. married 76.8 800 -2.19 
Pleural effusion 24 1.2 2.43 
Use of oral hypoglycemic agents 50 3.1 2.74 
Use of dIgitalis 15.6 13.1 2.00 
X-ray abnormalities (other than pleural 12.7 9.8 2.56 
effusion, pulmonary congestion or 
cardiomegaly) 
Normal chest X-ray 73.4 77.0 -2.34 
Cardiac arrest during prevIous MI 3.8 5.6 -2.44 
Symptoms of MI after qualifying exam 2.0 0.6 3.42 
Use of acetaminophen after qualifYIng exam 237 207 2.04 
ECG evidence of new MI after qualifYIng 16 0.5 2.98 
exam 
2. Continuous variables (mean value) 
Serum urea nitrogen/creatinine ratIO 15.1 14.8 2.56 
Inorganic phosphorus (mg/dl) 3.4 3.3 2.06 
Hematocnt (%J 44.3 44.7 -2.25 
II. Other variables selected as adjusting variables 
I. Categoncal variables (% of patients) 
Three or more previous MIs 3.3 2.6 1.06 
ST depreSSIOn (Minnesota Code 4.1 to 4.4) 22.0 20.7 0.92 
Employment status: full time 32.6 33.4 -0.47 
Persistent supraventncular rhythm 0.1 0.1 0.00 
(Minnesota Code 8.4.1) 
Peripheral edema l.l 1.5 -1.10 
HIstory of angIna pectoris 45.8 43.6 1.26 
History of sinus node dysfunction 1.5 12 0.77 
History of stroke I.7 15 0.57 
History of frequent VPBs (6 or more/mIn) 11.4 124 -0.87 
2. Contmuous variables (mean value) 
Heart rate on ECG (beats/min) 66.3 65.8 1.00 
MaxImal S depth (mm) in leads VI, V2 , V3 2.4 2.3 0.03 
EctopIc codes, T-R' interval (mm) 6.2 6.4 -0.96 
Age (yrJ 56.8 56.5 0.89 
Serum urea nitrogen (mg/dl) 17.2 16.9 1.86 
Serum uric acid (mg/dl) 6.9 6.9 -099 
III. Other variables selected for adjustment in PARIS I 
I. Categoncal variables (% of patients) 
Physical actiVIty: lIght or sedentary 70.5 71.9 -0.89 
Use of antiarrhythmic agents 13.6 13.0 0.44 
Use of insulin 3.7 3.8 -0.09 
Major Q/QS patterns (Minnesota Code 1.1.1 21.6 20.9 0.48 
to 1.1.7) 
ST elevatIOn (Minnesota Code 9.2) 3.1 2.8 0.53 
High amplitude R waves (Minnesota Code 4.1 4.4 -044 
8.1 I to 8.1 5) 
Use of beta-receptor blocking drugs 44.6 44.2 0.25 
Cardiomegaly on baseline chest X-ray 14.8 12.4 1.94 
Ectopic codes (runs or bigeminy) 15.1 13.6 1.13 
2. Continuous values (mean value) 
Body mass index 26.4 26.4 -0.29 
Male 26.4 26.4 -043 
Female 26.6 26.5 0.11 
Pulse rate (counts/mm) 70.4 699 0.20 
Serum glucose (mg/dlJ 108.4 106.1 1.81 
Absolute neutrophil count (not measured in 
PARIS II) 
End POInt 
AdJusted* 
A,B,C 
A,B,C 
A,B,C 
A,B,C 
A,B,C 
A,B,C 
A,B,C 
A,B,C 
A,B.C 
A,B.C 
A,B,C 
A.B,C 
A,B,C 
B,C 
A,B 
A,B 
C 
C 
A 
B 
C 
C 
A,B,C 
A,B,C 
A.B,C 
A,B 
C 
A 
(contmued) 
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Table 1 (continued) 
Basehne Variable 
IV Other vanables which may be climcally Important 
I. Categoncal variables (o/c of patients) 
Male 
White 
Age?: 60 yr 
No history of MI pnor to qualifYing MI 
New York Heart AssociatIOn class I 
History of ECG-documented arrhythmia 
History of congestive heart failure 
History of coronary arteriography 
History of intermittent claudicatIOn 
Use of long-acting antianginal medicatIOn 
Use of nitroglycerin or other coronary 
vasodllators 
U ~e of diurel1c drugs 
Use of anl1hypertenslve medlcal10n other 
than dIUretics 
Use of aspirin less than once a month 
2. Continuous vanables (mean value) 
Serum creatinine (mg/IOO m!) 
Serum cholesterol (mgl I 00 ml) 
Serum potas~ium (mEqlliter) 
SGOT (umts) 
Serum total blhrubin (mg/lOO ml) 
V Qualifying ECG classification ('7< of patients) 
Q/QS finding; 
PR/A PLBO 
83.0 84.7 
90.0 89.5 
41.1 39.4 
84.4 84.9 
51 9 52.8 
35.1 35.3 
104 9.5 
16.5 17.3 
4.9 5.1 
37.7 35.4 
44.7 454 
28.2 28.6 
4.9 5.1 
79.5 79.4 
1.2 J.2 
245.0 244.0 
4.6 4.5 
33.2 33.7 
07 07 
71 3 69.7 
Z Value 
PR/A-PLBO 
-128 
0.52 
0.94 
-0.36 
-0.50 
-0.09 
0.85 
-0.56 
-0.24 
1.33 
-0.36 
-0.29 
-0.24 
0.Q3 
0.33 
0.57 
0.62 
-0.83 
-1.42 
0.96 
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*Used for adju~tment of (A) total mortahty analysis. (8) coronary mortality analysIs, (C) coronary incidence 
analysIs. ECG = electrocardiogram: exam = examination: MI = myocardial mfarcl1on: PLBO = placebo 
group, PR/A = Persantine-aspirin group, SGOT = serum glutamiC oxaloaceticacid transaminase; VPBs = 
ventncular premature beats 
Follow-up and adherence. Of the 3.128 patients en•
rolled, 2,726 completed the closeout visit and 225 were 
reported as deceased, leaving 177 to be accounted for. Of 
these 177 patients, 151 were reported by the Clinical Centers 
to be alive as of July 31, 1984, 141 having been contacted 
directly. Of the 26 remaining patients, another 18 were 
subsequently traced by a search agency and found to be 
alive. Thus, the vital status of only eight patients (six in the 
Persantine plus aspirin group and two in the placebo group) 
was not known at the time the files were closed for the data 
analysis for this report (October 31, 1984). Four of these 
patients (three in the Persantine plus aspirin group and one 
in the placebo group) completed I year of follow-up. All 
eight patients were counted as alive for this report. 
Overall, only 8.5% of scheduled study visits were not 
completed. The mean time on study, measured for each 
patient from baseline examination to closeout visit (or July 
31, 1984, if the closeout visit was not completed), was 23.4 
months. 
Adherence to study prescription was assessed at each 
follow-up visit by pill count, questioning of the patient by 
the physician and testing for urine levels of drugs. The clinic 
physician assessments indicated that patients in the Persan-
tine plus aspirin and placebo groups, respectively, took 69.8 
and 74.3% of all capsules called for by the protocol. The 
percent of patients taking less than 20% of all capsules 
during the first year was 12.5 in the combination treatment 
Table 2. Distribution of Cumulative Percent of All Possible 
Capsules Taken at I Year and at 2 Years 
Percent Patients 
Cumulative Percent PR/A 
At I Year 
280 64.2 
60 to 79 103 
40 to 59 63 
20 to 39 6.7 
<20 12.5 
At 2 Year; 
280 59.8 
60 to 79 11.3 
40 to 59 60 
20 to 39 80 
<20 149 
PLBO = placebo group; PRI A = Persantine-aspirin group 
PLBO 
71.8 
9.8 
4.7 
4.4 
9.2 
67.5 
10.0 
5.8 
5.2 
114 
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Table 3. Biochemical Assessment of Adherence (number of 
patients tested in parentheses) 
Percent Patients 
PR/A PLBO 
Unnary salicylate> IO mg/dl 
Ba~ehne visit 14.7 (1,521) 14.1 (1,507) 
First follow-up Vl,It (4 mol 77 9 (10420) 107 (1.445) 
First annual vi,it 699(1.314) [3. [ 0,299) 
Second annual visit 68.0 (855) 130(849) 
Unnary dipyndamole positive 
Baseline visit 27(1,5[4) 2.3 (I,50l) 
First follow-up Visit (4 mol 710(10415) 2.2 (1,439) 
First annual Visit 67.3 (1.302) 44(1,283) 
Second annual viSIt 61 5 (847) 3.2 (840) 
PLBO = placebo group; PR/A = Per~antIne-aSplfln group. 
group and 9.2 in the placebo group; the corresponding per•
cent for 2 years was 14.9 and 1 1.4, respectively (Table 2). 
At baseline. 2.5% of patients had a positive urinary di•
pyridamole test (Table 3 );in PARIS I I % of patients had 
a positive test at baseline. These data suggest that the false 
positive rate is approximately 2 to 3%, although it is possible 
that a few patients were taking dipyridamole at the time of 
the baseline examination. The follow-up false positive test 
results for patients in the placebo group ranged from 2.2 to 
4.4% (Table 3). These results are consistent with the base-
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line findings and indicate that patients receIVIng placebo 
were not taking dipyridamole. The urinary dipyridamole 
results for the patients in the combination treatment group 
are consistent with the estimates of adherence based on pill 
count and questioning of the patient. 
The results for urinary salicylate at baseline indicated a 
higher percent of patients with levels greater than 10 mg/dl 
(14%) compared with the 5% observed at baseline in PARIS 
I. The PARIS II data may indicate that a small proportion 
of patients were taking aspirin or other salicylate-containing 
drugs at baseline. In the placebo group, the proportion of 
patients with positive urinary salicylate levels at the follow•
up visits was about the same as at baseline. In the Persantine 
pius aspirin group. the proportion of patients with a positive 
urinary salicylate level was similar to the proportion with a 
positive dipyridamole level. 
During the first 2 years of follow-up. the proportion of 
patients reported using non study aspirin-containing com•
pounds or platelet-affecting drugs (dipyridamole. sulfin•
pyrazone. phenylbutazone, indomethacin) during any given 
follow-up period was 7% or less. The differences between 
treatment groups were minor. 
Primary end points. Table 4 gives the percent for each 
treatment group (and Z values for the differences between 
percentages) of the fatal and nonfatal end points as classified 
by the Mortality and Morbidity Committee. With an average 
Table 4. Death by Cause and Nonfatal Events as Classified by the Mortality and 
Morbidity Committee 
Percent Patient, Percent 
Z Value Difference 
PR/A PLBO 
(n = 1,563) (n = 1,565) PR/A VS. PLBO PR/A vs. PLBO 
Death 
All cau~es* 7.1 73 -0.20 -3 
All cardiova,cular 6.1 66 -0.58 -8 
All noncardiovascular 0.9 0.6 082 50 
Cause unknown 01 0.1 0001 0 
Coronary heart disease* 4.9 5.2 -0.40 -6 
Sudden coronary 2.4 2.0 0.61 20 
Nonsudden coronary 2.6 3.2 -1.06 -19 
All cancer 0.8 0.5 0.90 60 
Other noncardiovascular 0.1 0.1 0.001 0 
Definite nonfatal MI 45 7 I -3.05 -37 
Definite or suspect MI 48 7.5 -3.19 -36 
Defimte ACI 1.8 1.3 1.01 38 
Definite or suspect ACI 6.0 5.6 0.54 7 
Defimte AP with 2.9 3.5 -0.81 -17 
hospitalization 
Definite or su,pect AP 3.6 41 -0.74 -12 
with hospitalizatIOn 
Definite ,troke 1.3 2.1 -1.64 -38 
DefinIte or su,pect stroke 1.3 23 -2.00 -43 
Coronary Incidence* 9.0 11.8 -2.57 -24 
*Pnmary end point Coronary Incidence defined as defimte nonfatal myocardial infarction (MI) or death 
due to recent or acute cardiac event. ACI = acute coronary InsuffiCiency: AP = angina pectori,: PLBO = 
placebo group; PR/A = Persantme-a,plrin group; VS. = versu,. 
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follow-up of 23.4 months, the percent of patients who died 
was 7.1 for the Persantine plus aspirin group (lll deaths) 
and 7.3 for the placebo group (\ 14 deaths) (Table 4). 
Life table rates for death. coronary death. and coronary 
incidence are given in Figure 1 and Table 5; percent dif•
ferences in rates and their confidence limits at each time 
point are also given. The first year rates for death were 4.2% 
for the Persantine plus aspirin group and 4.7% for the pla•
cebo group with a Z value for the difference of - 0.60. The 
2 year life table rates for death were 7.5% for the combi•
nation treatment group and 7.3% for the placebo treatment 
group with a Z value for the difference of 0.20. The Cox 
Z values comparing the life table curves were - 0.20, un•
adjusted, and - 0.47, adjusted for 22 baseline variables. 
For coronary death (about 70% of the total deaths). there 
was a 6% reduction at the end of the study in the combination 
treatment group compared with the placebo group (Z = 
-0.40, Table 4) and a 20% reduction in the 1 year life 
table rates (Z = - 1.11, Table 5). The corresponding 2 
year rates were 5.2 and 5.5%, respectively (Z = -0.28). 
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The Cox Z value~ comparing the two curves were -0.40, 
unadjusted, and - 0.77, adjusted for 21 variables. 
Coronary incidence for the Persantine plus aspirin group 
compared with the placebo group was reduced by 24% at 
the end of study (Z = - 2.57, Table 4), by 30% for the I 
year life table rates (Z = - 2.65. Table 5) and by 25% for 
the 2 year life table rates (Z = - 2.67. Table 5). The Cox 
unadjusted Z value was - 2.57 and the Z value adjusted 
for 22 baseline variables was - 2.61. The treatment dif•
ferences at 1 year and at end of study for coronary incidence 
were statistically significant by study criteria. 
The 2 year life table rates are quite comparable with the 
percent of patients with events at the end of study, as would 
be expected, since most patients were followed for close to 
2 years and only a few patients had a follow-up visit after 
the second annual visit. In all cases, the life table rates are 
slightly higher, but the treatment differences are of the same 
order of magnitude and the Z values are comparable. 
Other fatal and nonfatal events. Drug-placebo differ•
ences for cause-specific mortality were small. For nonfatal 
Table 5. End Point Life Table Rates. Z Value, and Percent Reduction 
Percent 950/c Confidence limits 
Event Rates Z value, Dlfference* for Percent Difference 
PR/A PLBO PRIA v, PLBO PR/A V5. PLBO Lower Upper 
Total death (mo) 
4 16 1 7 -028 - 6 -46 59 
8 2.8 33 -081 -15 -43 27 
12 4.2 47 -060 -11 -35 26 
16 5.1 5 3 - 029 - 4 -30 30 
20 59 63 - 0 46 - 6 -31 28 
24 7.5 73 0.20 3 -24 38 
Coronary death (mo) 
4 1.3 1 3 017 0 -43 94 
8 19 26 -1 22 -27 -53 20 
12 28 35 -Ill -20 -46 19 
16 3.6 40 -O.6Y -10 -39 27 
20 4.1 46 -065 -11 -38 30 
24 5.2 5 5 -028 - 5 -33 36 
Coronary mCldencet (mo) 
4 21 30 -1.61 -30 -55 9 
8 35 56 -283 -38 -55 -13 
12 5.5 79 -265 -30 -47 - 8 
16 7.2 9.1 - 1.94 -21 - 38 1 
20 84 107 -214 ··21 -39 - 1 
24 95 127 -267 -25 -42 - 4 
DefinIte nonfatal myocardIal 
mfarction (mo) 
4 08 I 8 - 2.41 -56 -77 -13 
8 1 7 34 - 303 -50 -70 -21 
12 3.0 50 - 281 -40 - 59 -14 
16 3.9 5 8 -no ·33 -51 - 5 
20 4.8 7.0 -249 -31 -52 - 5 
24 52 82 -303 -37 -55 -11 
* 
PRI A rate - PLBO rate 
tCoronary mCldence defined a, definIte nonfatal myocardIal infarcl\on and death due to recent or acute cardIac x 100. 
PLBO rate 
event. PLBO = placebo group. PR/A = Pen,antme-m,pmn group. vs. = ver,m. 
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Figure 1. Cumulative event rates, all patients. A, Death. all causes; 
B, coronary death; C, coronary incidence. PLBO = placebo; PR/A 
= Persantine-aspirin group. 
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events classified by the Mortality and Morbidity Committee, 
the differences for definite nonfatal myocardial infarction 
and for the combination of definite and suspect nonfatal 
myocardial infarction yielded Z values of - 3.05 and - 3.19, 
respectively (Table 4). The first year rates were 3.0 for 
Persantine plus aspirin and 5.0 for placebo patients (Z = 
-2.81, Table 5) and the corresponding 2 year rates were 
5.2 and 8.2, respectively (Z = - 3.03, Table 5). 
Table 6 shows the occurrence of other nonfatal cardio•
vascular events not reviewed by the Mortality and Morbidity 
Committee. The Persantine plus aspirin group showed lower 
incidence of definite intermittent cerebral ischemic attacks 
and of hospitalization for myocardial infarction as reported 
by the clinic physician (Z = - 3.11 and - 3.11, respec•
tively). More patients in the Persantine plus aspirin group 
than in the placebo group were hospitalized for gastroin•
testinal disorders, but the difference was not significant 
(Z = 1.69). 
Side effects and other findings. The Persantine plus 
aspirin group showed the expected side effects, reported by 
the patients as complaints or by their physicians as problems 
or reasons for discontinuing drug treatment (Table 7). Side 
effects included stomach pain, heartburn. nausea, gastroin•
testinal irritation and gastrointestinal bleeding. For most of 
these findings. the differences were large and yielded Z 
values of greater than 3.00. There were also more patients 
in the Persantine plus aspirin group who complaineq of 
headache. a known side effect of dipyridamole (Z = 4.67). 
Table 8 gives the percent of patients ever outside given 
limits for certain biochemical and clinical measurements. 
Higher proportions of patients in the combination treatment 
group than in the placebo group showed elevations in serum 
urea nitrogen. uric acid and creatinine. The drug-placebo 
differences for serum urea nitrogen and uric acid were highly 
statistically significant, but increases for individual patients 
were generally small and not associated with clinical prob•
lems. Fewer patients in the Persantine plus aspirin group 
than in the placebo group had a total serum bilirubin higher 
than 1.5 mg/dl. More patients in the combination group had 
a systolic blood pressure less than 100 mm Hg at some point 
during follow-up. Other changes in systolic and diastolic 
blood pressure were small. A larger proportion of patients 
in the Persantine plus aspirin group than in the placebo group 
had a hematocrit less than 35% at some time during the 
study. 
Subgroup analyses. Early in the study, before any study 
data were reviewed, the Data Monitoring Committee for•
mulated three subgroup hypotheses, namely, that the Per•
san tine-aspirin combination would have a beneficial effect 
on the three primary end points in patients at lower risk, 
that is, in one or more of the three (overlapping) baseline 
subgroups: a) patients in New York Heart Association func•
tional class I, b) patients with a history of only one myo•
cardial infarction (the qualifying event) at the time of entry 
lACC Vol. 7, No 2 
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Table 6. Nonfatal Events Reported by Clinic PhysicIans 
Definite de novo congestIve heart failure 
De novo arrhythmias 
Recurrent arrhythmias 
Defimte interrmttent cerebral IschemIC attacks 
Defimte peripheral arterial occlusion 
Defimte intermittent claudication (new) 
Defimte angina pectoris (new) 
Defimte angina pectoris (recurrent) 
CardIOvascular surgery 
Hospitalization for myocardial InfarctIon 
Hospitalization for gastrointestinal disorder 
Any hospitalization 
Percent Patients 
PR/A PLBO 
4.7 3.9 
2.0 3.0 
6.5 63 
07 2.0 
0.7 0.7 
40 3.8 
287 28.8 
619 60.6 
8.5 77 
44 7.0 
4.4 32 
40.0 395 
Z Values 
PR/A vs. PLBO 
1.10 
-1.44 
0.14 
-3 II 
0.00 
0.27 
-0.07 
0.52 
0.86 
-311 
169 
029 
PLBO = placebo group; PR/A = Persantine-aspinn group; vs. = versus. 
into the study, and c) patients not under prescription for 
digitalis at the time of entry into the study. These three 
subgroups were chosen on the basis of PARIS I data which 
suggested that Persantine-aspirin might be more effective 
in those subgroups than in the complementary subgroups. 
Class I versus class II patients. In PARIS II, coronary 
incidence at the end of I year of patient follow-up was lower 
in the Persantine plus aspirin group than in the placebo group 
for patients who were identified as in functional class I 
Table 7. Side Effects 
PatIent complaints 
Stomach pain 
Heart bum 
VomitIng 
Hematemesis. bloody stools and black. 
tarry stools. or both 
ConstIpatIon 
DiZZIness 
Headaches 
Symptoms reported by physiCians as problems 
Hematemesis. bloody stools and black. tarry 
stools, or both 
Symptoms suggestive of peptIC ulcer, gastritIs 
or erosion of gastric mucosa 
Reason for permanent or temporary discontinuation 
of study medication 
Stomach paIn 
Heartburn 
Nausea without vomiting 
Vomiting 
Hematemesis, bloody stools and black. tarry 
stools. or both 
Headaches 
compared with those who were in class II at the time of 
entry into the study (37% reduction compared with 25% 
reduction)(Table 9). The Z value for the Persantine plus 
aspirin versus placebo comparison among class I patients 
was - 2.18. None of the other Persantine plus aspirin versus 
placebo differences in event rates for class I or class II 
patients yielded Z values greater than 2.0. 
Patients with one infarction versus patients with previous 
infarction. Larger drug-placebo differences in coronary in-
Percent Patients Z Values 
PR/A PLBO PR/A vs PLBO 
140 6.6 6.79 
9.0 57 3.50 
2 I 08 2.85 
23 1.4 1.74 
2.3 1.1 2.63 
3.9 3.4 0.86 
7.8 39 467 
3.4 3.2 0.39 
15.2 9.8 4.56 
5.8 2.9 3.97 
26 2.0 1.20 
2.6 15 2.14 
1.2 0.1 3.73 
I 5 0.9 149 
2.4 I 2 255 
PLBO = placebo group; PR/A = Persantine-aspmn group; vs. = versus 
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Table 8. Patients Outside Given Limits for Laboratory and Clinical Measurements at Any 
Follow-up Visit 
Percent Patients Z Values 
PR/A PLBO PR/A vs. PLBO 
Measurements made at local c1imc at each follow-up VISIt 
Systolic blood pressure (mm Hg) 
<100 11.0 7.6 
56.5 
17.9 
4.0 
3.33 
-0.15 
1.44 
1.30 
:2:140 56.2 
:2:160 19.9 
:2:180 4.9 
Diastolic blood pressure (mm Hg) 
<~ 4.8 3.8 
46.4 
19.8 
3.2 
2.2 
1.41 
-0.21 
0.77 
-0.12 
2.37 
:2:~ %.1 
:2:95 20.9 
:2:110 3.1 
Percent hematocnt < 35 3.6 
Central laboratory measurements done annually 
Urea nitrogen :2: 26 mg/dl 12 I 6.2 
13.6 
19.1 
10.6 
5.9 
5.34 
6.10 
1.69 
Uric acid :2: 8.5 mg/dl 22 7 
Creatinine :2: 1.4 mg/dl 21.7 
SGOT :2: 55 units/ml 10.1 -0.43 
Total bilirubin :2: 1.5 mg/dl 3.4 -310 
Potassium < 3.4 mEq/L 2.6 3.2 -\.02 
PLBO = placebo group; PR/A = Persantine-aspirin group; SGOT = serum glutamic oxaloacettc acid 
transaminase; vs = versus. 
cidence at the end of I year of patient follow-up and at the 
end of the study were observed for patients who had only 
one myocardial infarction compared with those who had had 
one or more infarctions before the event which made the 
patient eligible for PARIS II. There was a 34% reduction 
in the Persantine plus aspirin group compared with the pla•
cebo group (Z = - 2.57) at the end of I year of patient 
follow-up and a 24% reduction at the end of the study (Z 
= - 2.25). The Z values for all other drug-placebo com•
parisons for subgroups defined by number of myocardial 
infarctions were less than 2.0. 
Patients taking versus those not taking digitalis. The 
largest drug-placebo differences in the subgroups defined a 
priori were observed for coronary incidence among nonusers 
of digitalis. The Persantine plus aspirin group was found to 
have a lower incidence (Z = - 3.45 for total events and Z 
= - 3.32 for first year events)(Table 9). Among users of 
digitalis (at entry into the study), the differences were small 
but favored the placebo group. 
Role of beta-receptor blockers. During the course of the 
study in October 1982, it became clear that a large pro•
portion (46%) of the patients enrolled in PARIS II were 
using beta-receptor blocking agents at entry and the Data 
Monitoring Committee decided to monitor this subgroup of 
patients to determine whether the Persantine-aspirin treat•
ment effects were the same whether or not a patient was 
taking a beta-receptor blocking agent. In the subgroup taking 
these agents, there was a large reduction in the Persantine 
plus aspirin group compared with the placebo group in oc•
currence of all the primary end points (Table 9). For coro•
nary incidence, Z = - 2.97 at the end of the study and Z 
= - 3.09 for first year events. In the complementary group 
(nonusers of beta-receptor blocking agents), there was a 
lower incidence in the combination treatment group than in 
the placebo group only for coronary incidence (overall and 
1 year) but the reduction was not as large as for those taking 
beta-receptor blocking agents (Table 9). 
Other subgroups that were not specified a priori were 
defined by 31 baseline variables and were monitored during 
the course of the study. None yielded large drug-placebo 
differences. 
Role of time from myocardial infarction to entry into 
study. The results for two other baseline variables were 
examined after the study ended and are given in Table 9. 
Patients were divided into two groups based on time from 
the qualifying myocardial infarction to the time of entry into 
the study. The median time of 85 days to entry was used 
to define the subgroups. Patients enrolled within 85 days of 
the qualifying myocardial infarction showed somewhat larger 
treatment differences with respect to coronary incidence 
than the patients enrolled more than 85 days after the acute 
event; the largest differences were observed during the sec•
ond year of follow-up. 
Role of presence or absence of QIQS changes in elec•
trocardiogram. The other subgroups examined were clas•
sified by presence or absence of QIQS changes in the elec-
Table 9. Percent of Events for Baseline Subgroups, Z Values and Percent Difference 
95% Confidence 
Percent Limits for Percent 
Percent Patients Z Value Z Value Differencet Difference 
PR/A PLBO PR/A vs. PLBO Subgroup Effects * PR/A VS. PLBO Lower Upper 
NYHA functional class 
Total death-first year 
Class I (n = 81 I, 826)§ 2.7 40 -1.44 -1.35 -33 -60 15 
Class II (n = 752, 739) 5.9 5.4 0.37 9 -29 64 
Total death-total follow-up 
Class I 4.9 58 -0.79 -0.88 -16 -44 28 
Class II 9.4 89 0.34 6 -23 46 
Coronary death-first year 
Class I 1.6 2.9 -1.77 -1.37 -45 -72 8 
Class II 4 I 4.2 -007 - 2 -40 60 
Coronary death-total follow-up 
Class I 32 4.1 -0.98 -0.95 -22 -53 29 
Class II 6.8 65 0.22 5 -29 53 
Coronary incldence:j:-first year 
Class I 4.3 6.8 -2.18 -0.58 -37 -58 4 
Class II 6.8 9.1 -163 -25 -47 6 
Coronary mcidence:j:-total follow-up 
Class I 7.6 10.3 -187 -019 -26 -46 2 
Class II 10.4 13.4 -1.81 -22 -41 2 
Number of myocardial infarctions 
Total death-first year 
One MI (n = 1,319, 1,328)§ 3.1 3.8 -1.03 -0.89 -18 -46 21 
Two or more Mis (n = 244, 237) 10.2 93 0.36 10 -36 90 
Total death-total follow-up 
One MI 5.9 6.2 -0.28 -0.26 -5 -29 29 
Two or more Mis 13.5 135 001 0 -36 57 
Coronary death-first year 
One MI 2.0 28 -124 -0.55 -29 -55 20 
Two or more Mis 7.0 7.6 -027 -8 -52 74 
Coronary death-total follow-up 
One MI 3.9 43 -0.45 -0.24 -9 -36 33 
Two or more Mis 10.2 105 -0 II -3 -43 64 
Coronary incldence:j:-first year 
One MI 4.5 68 -257 -0.60 -34 -52 -9 
Two or more Mis II I 13.9 -0.95 -20 -51 28 
Coronary mcidence:j:-total follow-up 
One MI 78 103 -2.25 -007 -24 -41 -3 
Two or more Mis 15.2 19.8 - 1.35 -23 -48 13 
Digitalis usage 
Total death-first year 
Nonusers (n = 1,319, 1,360)§ 3.3 38 -0.69 0.01 -13 -42 30 
Users (n = 244, 205) 9.4 107 -046 -12 -50 53 
Total death-total follow-up 
Nonusers 5.5 6.3 -0.86 1.01 -13 -35 18 
Users 15.6 13.7 0.57 14 -27 79 
Coronary death-first year 
Nonusers 2.0 29 - 1.51 073 -31 -58 12 
Users 74 7.8 -0.17 -5 -51 81 
Coronary death-total follow-up 
Nonusers 3.6 4.6 -130 1.47 -22 -46 13 
User; 12.3 98 085 26 -26 115 
Coronary mcidence:j:-first year 
Nonusers 4.4 74 -332 I 81 -41 -57 -19 
Users II.S 107 025 7 -37 81 
Coronary incidence:j:-total follow-up 
Nonusers 74 II 3 - 3.45 2.32 -35 -49 -16 
Users 17.2 14.6 074 18 -24 81 
(continued) 
Table 9 (continued) 
95% Confidence 
Percent Limits for Percent 
Percent PalIents Z Value Z Value Dlfferencet Difference 
PR/A PLBO PR/A vs. PLBO Subgroup Effects* PR/A Vi>. PLBO Lower Upper 
Beta-receptor blockmg drug usage 
Total death-first year 
Nonm,ers (n = 866, 874)§ 6.4 5.5 076 -239 16 -21 68 
Users (n = 697, 691) 16 3.6 -2.39 -56 -78 -12 
Total death-total follow-up 
Nonusers 9.5 8.7 0.56 -1.30 9 -19 47 
Users 42 5.5 -1.16 -24 -53 21 
Coronary death-first year 
Nonusers 44 4.1 0.28 -2.36 7 -32 66 
Users 0.9 2.7 -2.65 -67 -87 -22 
Coronary death-total follow-up 
Nonusers 6.7 6.1 0.54 -1.56 10 -23 58 
Users 2.7 42 -1.50 -36 -63 15 
Coronary mcidencet-first year 
Nonusers 7.9 9.4 -I 14 -202 -16 -39 14 
Users 2.6 5.9 -3.09 -56 -75 -25 
Coronary incidencet-total follow-up 
Nonusers 11.7 13.3 -102 -1.87 -12 -32 13 
Users 56 98 -2.97 -43 -61 -17 
Time from qualifYIng MI to entry 
Total death-first year 
:so85 days (n = 772, 818)§ 4.1 4.4 -025 0.23 -7 -41 50 
>85 days (n = 791,747) 4.3 5.0 -0.61 -14 -45 37 
Total death-total follow-up 
:so85 days 7.1 7.7 -0.44 -0.47 -8 -35 31 
>85 days 7.1 6.8 0.19 4 -28 50 
Coronary death-first year 
:so85 days 3.0 3.3 -037 059 -9 -48 56 
>85 days 2.7 3.7 -1.22 -27 -59 24 
Coronary death-total follow-up 
:so85 day, 4.9 5.5 -052 -0.37 -II -41 36 
>85 days 4.9 5.0 -002 - 2 -36 54 
Coronary incidencet-first year 
:so85 days 6.0 8.6 -199 -0.24 -30 -51 0 
>85 days 5.1 7.1 -168 -28 -52 6 
Coronary incidencet-total follow-up 
:so85 days 9.2 13.4 -2.67 -133 -31 -48 -9 
>85 days 8.7 9.9 -0.80 -12 -36 20 
Q Wave Changes at Qualifying MI 
Total death-first year 
Q wave changes (n = 1,114, 4.5 4.6 -0.11 077 -2 -33 44 
1,091)§ 
No changes (n = 449, 474) 3.6 49 -0.97 -27 -61 37 
Total death-total follow-up 
Q wave changes 7.7 7.1 0.51 134 8 -20 45 
No changes 5.6 76 -1.24 -26 -55 20 
Coronary death-first year 
Q wave change; 2.9 3.2 -0.46 0.80 -9 -44 44 
No changes 2.7 4.2 -1.28 -36 -69 28 
Coronary death-total follow-up 
Q wave changes 5.2 4.9 0.37 1.31 6 -25 54 
No changes 4.2 6.1 -1.29 -31 -61 22 
Coronary incldencet-first year 
Q wave changes 5.8 7.3 -1.42 1.43 -21 -42 9 
No changes 4.7 9.1 -2.63 -48 -69 -15 
Coronary Incidence:j:-total follow-up 
Q wave changes 100 10.8 -0.66 279 -7 -28 18 
No changes 6.5 13.9 -3.73 -53 -69 -30 
*This Z value is based on a comparison of the PR/A-PLBO difference in the first subgroup with that difference In the second or complementary 
PR/A (%) - PLBO (%) 
x 100. tCoronary death or defimte nonfatal myocardial Infarction. §Numbers in parentheses are the denominators subgroup. t 
- PLBO (%) 
for PR/A and PLBO groups, respectively. Denominators for three end POInts and two time-points are the same MI = myocardial Infarction; NYHA = 
New York Heart Association; PLBO = placebo group; PR/A = PersantIne-aspirin group; v;. = versus. 
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trocardiogram that documented the patient's myocardial 
infarction and eligibility for the study, In those patients with 
non-Q/QS electrocardiographic evidence of infarction there 
was a 53% reduction in coronary incidence in the Persantine 
plus aspirin group compared with the placebo group at the 
end of the study (Z = - 3,73), At the end of I year of 
patient follow-up, there was a 48% reduction in the com•
bination treatment group for the patients with non-Q infarcts 
(Z = - 2,63), For patients who had Q wave changes in 
the qualifying electrocardiogram, the drug-placebo percent 
difference in coronary incidence was - 21 % at the end of 
one year and - 7% at the end of the study, The correspond•
ing Z values were less than 2.0. 
All tests to determine whether the Persantine-aspirin 
treatment effects in one subgroup were different from the 
treatment effects in the complementary subgroup were not 
statistically significant by study criteria (see column 4 of 
Table 9). 
Data Audit Center review. The Data Audit Center, as 
part of its special review of each case of definite nonfatal 
myocardial infarction, doc4mented the criteria used by the 
Mortality and Morbidity Committee to classify each case. 
Table 10. Data Audit Center Review of Events ClassIfied as Coronary Incidence by the 
Mortality and Morbidity Committee 
PR/A 
I. Number of definite nonfatal myocardial mfarctwnio accordmg to amount of evidence for the 
classification 
Coronary death 77 
Q/QS changes with elevated enzyme., 27 
CK-MB and CK elevated 15 
CK-MB elevated. CK not elevated I 
CK elevated 7 
Other enzymes elevated 4 
Q/QS changes Without elevated enzymeio 2 
CK-MB and CK elevated (no Q/QS changes) 21 
CK-MB elevated, CK not done (no Q/QS change~) I 
CK elevated (no Q/QS changes) 6 
Other enzyme~ elevated (no Q/QS changes) 5 
CK-MB elevated. CK not elevated (no Q/QS changes) 0 
CK-MB negatIve, other enzymes elevated (no Q/QS change,) 
Coronary mCldence 140 
PLBO 
82 
36 
21 
0 
9 
6 
2 
33 
0 
9 
12 
8 
2 
184 
II Number of disagreements between Mortahty and MorbidIty Committee and climc physician n:gardmg 
classification of defimte myocardial lOfarctlon 
Reported findmgs 
Q/QS change~ with elevated enzymes 
Q/QS changeio WIthout elevated enzyme~ 
CK-MB and CK elevated (no Q/QS changes) 
CK elevated (no Q/QS change,) 
Other enzyme, elevated (no Q/QS changes) 
CK-MB elevated, CK not elevated (no Q/QS change,) 
CK-MB negatIve, other enzyme~ elevated (no Q/QS changes) 
Total 
Ca,e, Classified as Defimte Myocardial 
Infarction by Mortality and 
Morbidity CommIttee but Not by 
Clime Physician 
PR/A 
o 
4 
3 
2 
o 
o 
10 
PLBO 
o 
7 
1 
6 
6 
22 
Ca,es Cla"lfied a, Defimte Myocardial Infarction 
by Chmc PhYSICian but Not by Mortahty 
and Morbidity Committee 
Q/QS findlOg, With elevated enzymes 
Enzymes elevated (no Q/QS change,) 
No enzymes elevated (no Q/QS change,) 
Total 
o 
o 
I 
3 
o 
4 
CK-MB = creatme klOa,e, MB fractIon, PLBO = placebo group; PR/A = Pen,antme-asplrin group. 
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The numbers of cases in each treatment group are given in 
Table 10, classified by the amount of evidence which sup•
ported the diagnosis of myocardial infarction. The strongest 
evidence to support the classification occurred when there 
were new QIQS changes in the electrocardiograms at the 
time of the clinical onset of a recurrent myocardial infarction 
and elevations in one or more specific enzymes [creatine 
kinase (CK)-MB and total CK or total CK alone] or other 
enzymes as specified in the guidelines followed by the Mor•
tality and Morbidity Committee. Twenty-seven cases in the 
Persantine plus aspirin group and 36 cases in the placebo 
group met these criteria (Table 10). The number of cases 
in the placebo group compared with the combination treat•
ment group was also higher for each of the other categories 
of evidence. The frequency of disagreements between the 
clinic physician classification of a nonfatal event and the 
Mortality and Morbidity Committee classification by cate•
gory was also determined by the Data Audit Center. In the 
Persantine plus aspirin group there were disagreements in 
10 (7%) of 140 of the cases classified as definite myocardial 
infarction by the Mortality and Morbidity Committee. In 
the placebo group there were 22 (12%) of 184. In addition, 
four placebo cases and one Persantine plus aspirin case were 
classified as definite myocardial infarction by the clinic phy•
sician but not by the Mortality and Morbidity Committee. 
The conclusion of the Data Audit Center review of the 
Mortality and Morbidity Committee procedures was that the 
classification of nonfatal and fatal events had been con•
ducted according to established, documented guidelines and 
criteria. The Data Audit Center further concluded that the 
Mortality and Morbidity Committee was blind with respect 
to each patient's treatment assignment and that there was 
no evidence of bias in the classification of events. 
Discussion 
Effect on coronary incidence and mortality and all 
cause mortality. At the end of the study, after an average 
of 23.4 months follow-up, coronary incidence was 24% 
lower in the Persantine plus aspirin group than in the placebo 
group. Coronary mortality was 6% lower for the total fol•
low-up period and all cause mortality was 3% lower in the 
drug group compared with the placebo group. First year life 
table rates for Persantine plus aspirin patients were 30, 20 
and 11 % lower than the rates for patients receiving placebo 
for coronary incidence, coronary mortality and all cause 
mortality, respectively. The differences in coronary inci•
dence at 1 year (Z = - 2.65) and at the end of the study 
(Z = - 2.57) were statistically significant by study criteria 
(Z = ± 2.49). The reduced rates of coronary incidence 
largely reflected lower rates of definite nonfatal myocardial 
infarction in the combination treatment group compared with 
the placebo group. 
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With this Per1>antine-aspirin effect on definite nonfatal 
myocardial infarction, the question arises as to why there 
was little effect on coronary mortality and no effect on all 
cause mortality. It is possible that with a longer follow-up 
period, the Persa~tine-aspirin effect on nonfatal myocardial 
infarction would tlt..reflected in lower mortality rates, even 
after the treatment is\,liscontinued. In the Coronary Drug 
Project (29), one of the-'1lJ:l0lesterol-lowering agents (nico•
tinic acid) showed a significant beneficial effect on nonfatal 
myocardial infarction but no effect on mortality during the 
6 year course of the study. Long-term posttrial follow-up 
of these patients showed a significant reduction of mortality 
for patients previously treated with the drug compared with 
those previously treated with placebo (30). In the present 
study, the mortality rate was significantly greater in patients 
enrolled in the study with more than one myocardial in•
farction, supporting the concept that a nonfatal myocardial 
infarction will, in time, result in an increased fatality rate. 
Low risk versus high risk patients and Q wave versus 
non-Q wave infarction. In PARIS II, as well as in PARIS 
I, there was strong evidence that patients with low risk, that 
is, patients not using digitalis, patients in New York Heart 
Association functional class I and patients with only one 
myocardial infarction were more likely to benefit from Per•
santine-aspirin treatment than patients who were considered 
at high risk, that is, patients who used digitalis or were in 
functional class II or had had at least two myocardial in•
farctions. There was also some evidence that treatment should 
be started early, that is, patients enrolled within 85 days of 
the qualifying infarct showed a larger treatment difference 
than those patients enrolled later. Although, in a statistical 
sense, the results for patients with a Q wave infarct were 
not different from those in patients with a non-Q wave 
infarct as defined on the basis of the qualifying electrocar•
diogram, there was a strong suggestion that the effect of 
Asasantine was particularly marked in the non-Q wave group. 
As Marmor et al. (31) have emphasized, on the basis of 
their study of 200 patients with acute myocardial infarction, 
those with a subendocardial myocardial infarction (non-Q 
wave infarct) compared with those with initial transmural 
infarction (Q wave infarct) are more susceptible to rein•
farction (43 compared with 8%). Early reinfarction in both 
groups was associated with an increase in mortality of 128%. 
Role of beta-blocker agents. Review of the Beta-Blocker 
Heart Attack Trial results (32) indicated that propranolol 
prolonged survival primarily in patients who had a Q wave 
infarct. No mortality differences were observed for patients 
who had a non-Q wave infarct. In PARIS II, we have noted 
a larger effect of Persantine and aspirin in the subgroup of 
patients using beta-receptor blocking agents than in the 
subgroup who were not using thestt agents at the time of 
entry into the study. There was also no evidence of detri•
mental effects of the use of Persantine and aspirin and beta-
lACC Vol 7. No 2 
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receptor blocking agents together. The results of PARIS II 
and the Beta-Blocker Heart Attack Trial suggest that there 
may be an advantage to taking all three of these agents in 
the first 12 to 24 months after myocardial infarction. 
Implication. PARIS II is the first large-scale random•
ized controlled trial to yield significant positive effects of 
platelet-active drugs in reducing incidence of recurrent ma•
jor coronary events, a prespecified primary end point, in 
patients recovered from myocardial infarction. The design 
of PARIS II does not permit an assessment of the relative 
contribution of the two components of the Persantine and 
aspirin combination to the observed favorable outcome. 
Conclusions 
1. Coronary incidence (definite nonfatal myocardial in•
farction plus death due to recent or acute cardiac event) in 
the Persantine and aspirin group compared with the placebo 
group was significantly lower by 30% at 1 year of patient 
follow-up (Z = - 2.65) and 24% overall (Z = - 2.57). 
2. All cause mortality was similar in the two groups. 
Coronary mortality (death due to recent or acute cardiac 
event) was lower in the Persantine and aspirin group but 
not significantly so-20% at 1 year and 6% overalL 
3. In regard to three prior subgroup hypotheses-con•
cerning low risk patients, that is, those with a) only one 
infarct, b) in New York Heart Association functional class 
I, or c) not receiving digitalis treatment at baseline-Per•
santine plus aspirin treatment compared with placebo showed 
a greater percent reduction in all primary end points for 
those with these characteristics compared with those without 
them. The reduction in risk of a coronary event was largest 
for those not receiving digitalis treatment. 
4. A sizable proportion (44%) of patients were receiving 
a beta-receptor blocking agent at entry and most continued 
to take this medication during the course of the study. The 
beneficial effect of Persantine plus aspirin compared with 
placebo on coronary mortality and coronary incidence tended 
to be greater for the patients receiving a beta-receptor block•
ing drug at baseline than for those not receiving this med•
ication. There was no evidence of detrimental effects of the 
use of Persantine plus aspirin and a beta-receptor blocking 
drug together. 
5. A large difference between Persantine plus aspirin and 
placebo for coronary incidence at the end of the study was 
observed for the subgroup of patients whose qualifying myo•
cardial infarction was classified as non-Q wave infarction. 
The drug-placebo differences for the complementary group 
were smalL 
6. Adverse effects of Persantine plus aspirin were infre•
quent and were similar to those noted in PARIS I, that is, 
gastrointestinal irritation or bleeding, headache, increase in 
serum urea nitrogen levels and occurrence of hyperuricemia. 
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